menu
    • menu

    Company profile for GigaGen

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    GigaGen is advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers by leveraging industry-leading, single-cell technologies. Our technology uniquely captures and recreates complete immune repertoires as functional antibody libraries. This approach has enabled the creation of the first recombinant polyclonal immunoglobulin therapies, which overcome current limitatio...
    GigaGen is advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers by leveraging industry-leading, single-cell technologies. Our technology uniquely captures and recreates complete immune repertoires as functional antibody libraries. This approach has enabled the creation of the first recombinant polyclonal immunoglobulin therapies, which overcome current limitations of plasma-based products.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    GigaGenUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    One Tower Place, Suite 750 South San Francisco, CA 94080
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.gigagen.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    GigaGen Doses 1st Patient in Ph 1 of GIGA-2339 for Hepatitis B
    GigaGen Doses 1st Patient in Ph 1 of GIGA-2339 for Hepatitis B

    19 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/19/2983574/0/en/GigaGen-Doses-First-Patient-in-Phase-1-Trial-of-Recombinant-Polyclonal-Drug-Candidate-GIGA-2339-for-Hepatitis-B-Virus.html

    GLOBENEWSWIRE
    19 Nov 2024
    Share Share
    GigaGen garners up to $135M BARDA bucks to beat botulism
    GigaGen garners up to $135M BARDA bucks to beat botulism

    03 Oct 2024

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/grifols-gigagen-garners-135m-barda-tackle-botulinum-biothreat

    FIERCE BIOTECH
    03 Oct 2024
    Share Share
    GigaGen Doses First GIGA-564 Anti-CTLA-4 Solid Tumor Patient
    GigaGen Doses First GIGA-564 Anti-CTLA-4 Solid Tumor Patient

    20 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/20/2884820/0/en/GigaGen-Doses-First-Patient-in-Phase-1-Trial-of-Anti-CTLA-4-Oncology-Drug-Candidate-GIGA-564-in-Advanced-Solid-Tumors.html

    GLOBENEWSWIRE
    20 May 2024
    Share Share
    GigaGen Receives FDA Clearance of IND to Begin Phase 1 Trial of GIGA-564
    GigaGen Receives FDA Clearance of IND to Begin Phase 1 Trial of GIGA-564

    12 Dec 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/12/12/2794694/0/en/GigaGen-Receives-FDA-Clearance-of-IND-to-Begin-Phase-1-Trial-of-Oncology-Drug-Candidate-GIGA-564-in-Solid-Tumors.html

    GLOBENEWSWIRE
    12 Dec 2023
    Share Share
    GigaGen Granted Expansion of Contract to Develop Synthetic Human Antibody
    GigaGen Granted Expansion of Contract to Develop Synthetic Human Antibody

    19 Oct 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/10/19/2763125/0/en/GigaGen-Granted-Expansion-of-Contract-with-US-Department-of-Defense-to-Develop-Synthetic-Human-Antibody-Treatments-for-Botulinum-Neurotoxins.html

    GLOBENEWSWIRE
    19 Oct 2023
    Share Share
    GigaGen Partners with the National Cancer Institute to Advance Oncology Drug
    GigaGen Partners with the National Cancer Institute to Advance Oncology Drug

    28 Sep 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/09/28/2751133/0/en/GigaGen-Partners-with-the-National-Cancer-Institute-to-Advance-Oncology-Drug-Candidate-GIGA-564.html

    GLOBENEWSWIRE
    28 Sep 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search